Last reviewed · How we verify
KBP-5209
At a glance
| Generic name | KBP-5209 |
|---|---|
| Sponsor | Sihuan Pharmaceutical Holdings Group Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase II Umbrella Study Directed by Next Generation Sequencing (PHASE2)
- A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KBP-5209 CI brief — competitive landscape report
- KBP-5209 updates RSS · CI watch RSS
- Sihuan Pharmaceutical Holdings Group Ltd. portfolio CI